Oxemia 50 Tablet

Oxemia 50 is particularly beneficial for patients undergoing dialysis as well as those with non-dialysis-dependent CKD. The tablet is administered orally, offering a convenient alternative to injectable therapies. Clinical studies have demonstrated its efficacy in increasing hemoglobin concentrations while maintaining a favorable safety profile. Common adverse effects may include mild gastrointestinal disturbances, headache, and hypertension, though these are generally manageable.

Oxemia 50 should be used under medical supervision, with regular monitoring of hemoglobin levels, blood pressure, and iron parameters to optimize therapeutic outcomes and minimize risks. It is contraindicated in patients with uncontrolled hypertension or hypersensitivity to Desidustat or any excipients. Overall, Oxemia 50 Tablet represents an effective and well-tolerated option for managing anemia in CKD, improving patient quality of life and reducing dependence on injectable treatments.